Table 2 Expression of c-Rel, p50 and p65 in different stage of HPV16
Negative Control (n = 37) | Early Infection 36) | Late Infection(n = 142) | |||||
|---|---|---|---|---|---|---|---|
hr-HPVs(-) without lesion | HPV16( +) cervix without lesion /LSIL | χ2 | P | HPV16( +) HSIL/infiltrating carcinoma | χ2 | P | |
c-Rel | |||||||
Negative (%) | 26 (70.3) | 17 (47.2) | 5.693 | 0.017 | 38(26.8) | 6.229 | 0.044 |
Low (%) | 6 (16.2) | 5 (13.9) | 38 (26.8) | ||||
High (%) | 5 (13.5) | 14 (38.9) | 66 (46.4) | ||||
NF-ĸB p65 | |||||||
negative (%) | 26 (70.3) | 14 (38.8) | 10.019 | 0.007 | 53 (37.4) | 1.033 | 0.597 |
Low (%) | 9 (24.3) | 11 (30.6) | 55 (38.7) | ||||
High (%) | 2 (5.4) | 11 (30.6) | 34 (23.9) | ||||
NF-ĸB p50 | |||||||
Negative (%) | 23 (62.2) | 19 (52.8) | 0.753 | 0.686 | 40 (28.2) | 8.014 | 0.018 |
Low (%) | 9 (24.3) | 10 (27.8) | 66 (46.4) | ||||
High (%) | 5 (13.5) | 7 (19.4) | 36 (25.4) | ||||